NEWS 17 MAY 21 CA/CAplus enhanced with additional kind codes for German patents

NEWS 18 MAY 22 CA/CAplus enhanced with IPC reclassification in Japanese patents

NEWS 19 JUN 27 CA/CAplus enhanced with pre-1967 CAS Registry Numbers

NEWS 20 JUN 29 STN Viewer now available

NEWS 21 JUN 29 STN Express, Version 8.2, now available

NEWS 22 JUL 02 LEMBASE coverage updated

NEWS 23 JUL 02 LMEDLINE coverage updated

NEWS 24 JUL 02 SCISEARCH enhanced with complete author names

NEWS 25 JUL 02 CHEMCATS accession numbers revised

NEWS 26 JUL 02 CA/CAplus enhanced with utility model patents from China

NEWS 27 JUL 16 CAplus enhanced with French and German abstracts

NEWS 28 JUL 18 CA/CAplus patent coverage enhanced

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items.

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:10:19 ON 25 JUL 2007

=> file .mymstn

'JICST-EPLUS' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):ignore

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

0.21 0.21

FILE 'MEDLINE' ENTERED AT 10:10:41 ON 25 JUL 2007

FILE 'AGRICOLA' ENTERED AT 10:10:41 ON 25 JUL 2007

FILE 'BIOSIS' ENTERED AT 10:10:41 ON 25 JUL 2007 Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 10:10:41 ON 25 JUL 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'LIFESCI' ENTERED AT 10:10:41 ON 25 JUL 2007 COPYRIGHT (C) 2007 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 10:10:41 ON 25 JUL 2007

COPYRIGHT (C) 2007 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 10:10:41 ON 25 JUL 2007 Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> VH and VL and antibody and catalytic (w) antibody

VH IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s l1 and polypeptide L2 6 L1 AND POLYPEPTIDE

=> d ibib abs 12 1-6

SOURCE:

L2 ANSWER 1 OF 6 MEDLINE on STN ACCESSION NUMBER: 96279092 MEDLINE DOCUMENT NUMBER: PubMed ID: 8663068

TITLE: Selection of linkers for a catalytic single-chain

antibody using phage display technology.

AUTHOR: Tang Y; Jiang N; Parakh C; Hilvert D

CORPORATE SOURCE: Departments of Chemistry and Molecular Biology, The Scripps

Research Institute, La Jolla, California 92037, USA. The Journal of biological chemistry, (1996 Jun 28) Vol.

271, No. 26, pp. 15682-6.

Journal code: 2985121R. ISSN: 0021-9258.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)

(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199608

ENTRY DATE: Entered STN: 28 Aug 1996

Last Updated on STN: 3 Feb 1997 Entered Medline: 20 Aug 1996

Phage display has been evaluated as a means of rapidly selecting tailored linkers for single-chain antibodies (scFvs) from protein linker libraries. Preliminary experiments with a conventional linker failed to yield a functional single-chain version of a catalytic antibody with chorismate mutase activity. A random linker library was therefore constructed in which the genes for the heavy and light chain variable domains were linked by a segment encoding an 18-amino acid polypeptide of variable composition. The scFv repertoire (approximately 5 x 10(6) different members) was displayed on filamentous phage and subjected to affinity selection with hapten. The population of selected variants exhibited significant increases in binding activity but retained considerable sequence diversity. Screening 1054 individual variants subsequently yielded a catalytically active scFv that was produced efficiently in soluble form. Sequence analysis revealed a conserved proline in the linker two residues after the VH C terminus and an abundance of arginines and prolines at other positions as the only common features of the selected tethers. There are apparently many viable solutions to the problem of linking individual VH and VL domains, but subtle differences in sequence dramatically influence the production, stability, and recognition properties of the scFv. The success of these experiments suggests that phage display will be generally useful for identifying peptide sequences for covalently linking any two protein domains.



L2 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:438341 BIOSIS DOCUMENT NUMBER: PREV200300438341

TITLE: Changes in structure and dynamics of the Fv fragment of a

catalytic antibody upon binding of

inhibitor.

AUTHOR(S): Kroon, Gerard J. A.; Mo, Huaping; Martinez-Yamout, Maria

A.; Dyson, H. Jane [Reprint Author]; Wright, Peter E.

[Reprint Author]

CORPORATE SOURCE: Department of Molecular Biology, Scripps Research

Institute, 10550 N. Torrey Pines Road, MB2, La Jolla, CA,

92037, USA

dyson@scripps.edu; wright@scripps.edu

SOURCE: Protein Science, (July 2003) Vol. 12, No. 7, pp. 1386-1394.

print.

ISSN: 0961-8368.

DOCUMENT TYPE:

Article English

LANGUAGE: ENTRY DATE:

Entered STN: 24 Sep 2003

Last Updated on STN: 24 Sep 2003

AB Binding of the product inhibitor p-nitrophenol to the monoclonal esterolytic antibody NPN43C9 has been investigated by performing

NMR spectroscopy of the heterodimeric variable-domain fragment (Fv) of the

antibody in the presence and absence of inhibitor. Structural

information from changes in chemical shift upon binding has been related

to the changes in local dynamics in the active site of the catalytic antibody using NMR relaxation measurements.

Significant changes in the chemical shifts of the backbone resonances upon binding extend beyond the immediate vicinity of the antigen binding site into the interface between the two associated polypeptides that

form the Fv heterodimer, a possible indication that the binding of ligand causes a change in the relative orientations of the component light (

VL) and heavy (VH) chain polypeptides.

Significant differences in backbone dynamics were observed between the free Fv and the complex with p-nitrophenol. A number of resonances, including almost all of the third hypervariable loop of the light chain (L3), were greatly broadened in the free form of the protein. Other residues in the antigen-binding site showed less broadening of resonances, but still required exchange terms (Rex) in the model-free dynamics analysis, consistent with motion on a slow timescale in the active site region of the free Fv. Binding of p-nitrophenol caused these resonances to sharpen, but some Rex terms are still required in the analysis of the backbone dynamics. We conclude that the slow timescale motions in the antigen-binding site are very different in the bound and free forms of the Fv, presumably due to the damping of large-amplitude motions by the bound inhibitor.

L2 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:857619 CAPLUS

DOCUMENT NUMBER: 143

141:348835

TITLE: Production of antibodies with covalently

reactive antigen analogues for treating autoimmune disease, cancer, infection and Alzheimer's disease.

INVENTOR(S): Paul, Sudhir; Nishiyama, Yasuhiro

PATENT ASSIGNEE(S): The University of Texas, USA

SOURCE: PCT Int. Appl., 187 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
WO 2004-US9398
     WO 2004087735
                                  20041014
                           A2
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
                              TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
             TJ, TM, TN, TR,
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
                                                                       .20040326
                                  20041014
                                               CA 2004-2520381
     CA 2520381
                           A1
                                  20060118
                                              EP 2004-758448
     EP 1615946
                           A2
                                                                       20040326
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
     US 2007105092
                           A1
                                  20070510
                                              US 2006-581294
                                                                       20060601
PRIORITY APPLN. INFO.:
                                               US 2003-458063P
                                                                    P 20030326
                                               US 2004-534689P
                                                                    P 20040108
                                               WO 2004-US9398
                                                                    W 20040326
AB
     Improved methods for the production, selection and inhibition of proteolytic
     or catalytic and covalent antibodies are disclosed. The methods
     use covalently reactive polypeptide antigen analogs (pCRAs) and
     water-binding pCRAs (pCRAWs) to stimulate the production of antibodies
        The invention also provides methods for screening antibodies
     from phage display antibody libraries. The antibodies
     may be monoclonal antibodies, polyclonal antibodies,
     antibody fragments, IgG, IgM, IgA, IgD, IgE, VH or
          These antibodies are specific to pCRAs containing
     gp120, VIP, factor VIII, EGF receptor, CD4, β-amyloid peptide 1-40 or
     1-42, etc., and are passive immunotherapy of infection, blood coagulation
     disorder, cancer, autoimmune disease, alloimmune disease,
     lymphoproliferative disease, hepatitis C, Alzheimer's disease, etc.
     ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:
                          2003:513781 CAPLUS
DOCUMENT NUMBER:
                          140:14270
                          Changes in structure and dynamics of the Fv fragment
TITLE:
                          of a catalytic antibody upon
                          binding of inhibitor
                          Kroon, Gerard J. A.; Mo, Huaping; Martinez-Yamout,
AUTHOR (S):
                          Maria A.; Dyson, H. Jane; Wright, Peter E.
                          Department of Molecular Biology and Skaggs Institute
CORPORATE SOURCE:
                          of Chemical Biology, The Scripps Research Institute,
                          La Jolla, CA, 92037, USA
SOURCE:
                          Protein Science (2003), 12(7), 1386-1394
                          CODEN: PRCIEI; ISSN: 0961-8368
PUBLISHER:
                          Cold Spring Harbor Laboratory Press
DOCUMENT TYPE:
                          Journal
LANGUAGE:
                          English
     Binding of the product inhibitor p-nitrophenol to the monoclonal
     esterolytic antibody NPN43C9 has been investigated by performing
     NMR spectroscopy of the heterodimeric variable-domain fragment (Fv) of the
     antibody in the presence and absence of inhibitor. Structural
     information from changes in chemical shift upon binding has been related to
     the changes in local dynamics in the active site of the catalytic
     antibody using NMR relaxation measurements. Significant changes
     in the chemical shifts of the backbone resonances upon binding extend beyond
     the immediate vicinity of the antigen binding site into the interface
     between the two associated polypeptides that form the Fv
     heterodimer, a possible indication that the binding of ligand causes a
     change in the relative orientations of the component light (VL)
     and heavy (VH) chain polypeptides. Significant
     differences in backbone dynamics were observed between the free Fv and the
```

20040326

complex with p-nitrophenol. A number of resonances, including almost all of the third hypervariable loop of the light chain (L3), were greatly broadened in the free form of the protein. Other residues in the antigen-binding site showed less broadening of resonances, but still required exchange terms (Rex) in the model-free dynamics anal., consistent with motion on a slow timescale in the active site region of the free Fv. Binding of p-nitrophenol caused these resonances to sharpen, but some Rex terms are still required in the anal. of the backbone dynamics. We conclude that the slow timescale motions in the antigen-binding site are very different in the bound and free forms of the Fv, presumably due to the damping of large-amplitude motions by the bound inhibitor.

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

38

ACCESSION NUMBER: 1997:594353 CAPLUS

DOCUMENT NUMBER: 127:289747

REFERENCE COUNT:

TITLE: Cleavage specificity of a proteolytic antibody

light chain and effects of the heavy chain variable

THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS

domain

AUTHOR(S): Sun, Mei; Gao, Qing-Sheng; Kirnarskiy, Leonid; Rees,

Anthony; Paul, Sudhir

CORPORATE SOURCE: Department of Anesthesiology and Eppley Cancer

Research Institute, University of Nebraska Medical

Center, Omaha, NE, 68198-6830, USA

SOURCE: Journal of Molecular Biology (1997), 271(3), 374-385

CODEN: JMOBAK; ISSN: 0022-2836

PUBLISHER: Academic DOCUMENT TYPE: Journal LANGUAGE: English

The recombinant light chain (L chain) of an antibody raised by immunization with vasoactive intestinal polypeptide (VIP)

cleaved this peptide on the C-terminal side of basic residues. The major sites of cleavage in VIP were two adjacent peptide bonds, Lys20-Lys21 and Lys21-Tyr22. Lower levels of cleavage were evident at Arg14-Lys15 and Lys15-Gln16. Hydrolysis of radiolabeled VIP by the L chain was inhibited by two serine protease inhibitors, diisopropylfluorophosphate and aprotinin, but not by soybean or lima bean trypsin inhibitors or inhibitors of other classes of proteases. To probe the role of the VH domain, single chain Fv constructs composed of the VL

domain of the anti-VIP L chain linked via a 14-residue peptide to its natural VH domain partner or an irrelevant anti-lysozyme VH domain (hybrid FV) were prepared The anti-VIP FV hydrolyzed VIP

with Ks 21.4-fold lower than the L chain and 250-fold lower than the hybrid FV, suggesting increased affinity for the substrate ground state due to the anti-VIP VH domain. The kinetic efficiency (kcat/Ks) of the anti-VIP FV was 6.6-fold greater compared to the L chain and 29.4-fold greater compared to the hybrid Fv. Peptide-MCA substrates unrelated in sequence to VIP were hydrolyzed by the anti-VIP Fv and L chain at equivalent rates. These observations lead to a model of catalysis by the anti-VIP Fv in which the essential catalytic residues are located in

the VL domain and addnl. residues from the VH domain

are involved in high affinity binding of the substrate.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:391215 CAPLUS

DOCUMENT NUMBER: 125:80129

TITLE: Selection of linkers for a catalytic single-chain

antibody using phage display technology

AUTHOR(S): Tang, Ying; Jiang, Ning; Parakh, Cushrow; Hilvert,

Donald

CORPORATE SOURCE: Dep. Chem. Mol. Biol., Scripps Res. Inst., La Jolla,



CA, 92037, USA

SOURCE:

Journal of Biological Chemistry (1996), 271(26),

15682-15686

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER:

American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE: LANGUAGE: Journal English

Phage display has been evaluated as a means of rapidly selecting tailored AB linkers for single-chain antibodies (scFvs) from protein linker libraries. Preliminary expts. with a conventional linker failed to yield a functional single-chain version of a catalytic antibody with chorismate mutase activity. A random linker library was therefore constructed in which the genes for the heavy and light chain variable domains were linked by a segment encoding an 18-amino acid polypeptide of variable composition The scFv repertoire (≈5+106 different members) was displayed on filamentous phage and subjected to affinity selection with hapten. The population of selected variants exhibited significant increases in binding activity but retained considerable sequence diversity. Screening 1054 individual variants subsequently yielded a catalytically active scFv that was produced efficiently in soluble form. Sequence anal. revealed a conserved proline in the linker two residues after the VH C terminus and an abundance of arginines and prolines at other positions as the only common features of the selected tethers. There are apparently many viable solns. to the problem of linking individual VH and VL domains, but subtle differences in sequence dramatically influence the production, stability, and recognition properties of the scFv. The success of these expts. suggests that phage display will be generally useful for identifying peptide sequences for covalently linking any two protein domains.

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	0	VH adj antibody and VL adj antivodt	US-PGPUB; USPAT; DERWENT	OR	ON	2007/07/25 09:49
L2	64	VH adj antibody and VL adj antibody	US-PGPUB; USPAT; DERWENT	OR	ON	2007/07/25 09:50
L3	4	l2 and catalytic adj antibody	US-PGPUB; USPAT; DERWENT	OR	ON	2007/07/25 09:50